190 related articles for article (PubMed ID: 25620423)
21. HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Minami T; Kijima T; Otani Y; Kohmo S; Takahashi R; Nagatomo I; Hirata H; Suzuki M; Inoue K; Takeda Y; Kida H; Tachibana I; Kumanogoh A
Mol Cancer Ther; 2012 Apr; 11(4):830-41. PubMed ID: 22389470
[TBL] [Abstract][Full Text] [Related]
22. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
Lu J; Zhou K; Yin X; Xu H; Ma B
Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
[TBL] [Abstract][Full Text] [Related]
23. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
Liang D; Chen Q; Guo Y; Zhang T; Guo W
Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
[TBL] [Abstract][Full Text] [Related]
24. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
25. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
[TBL] [Abstract][Full Text] [Related]
27. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates.
Lyu A; Fang L; Gou S
Eur J Med Chem; 2014 Nov; 87():631-42. PubMed ID: 25305330
[TBL] [Abstract][Full Text] [Related]
31. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
[TBL] [Abstract][Full Text] [Related]
33. RON confers lapatinib resistance in HER2-positive breast cancer cells.
Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
[TBL] [Abstract][Full Text] [Related]
34. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
35. Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.
Chen Y; Yu W; Jiang CC; Zheng JG
Molecules; 2018 Jun; 23(6):. PubMed ID: 29925769
[TBL] [Abstract][Full Text] [Related]
36. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Wang DD; Ma L; Wong MP; Lee VH; Yan H
PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
[TBL] [Abstract][Full Text] [Related]
39. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
[TBL] [Abstract][Full Text] [Related]
40. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
